CKMSynced Forum

Embracing a holistic approach to DKD, CVD and CKM comorbidities with empagliflozin

The cardiovascular, kidney, and metabolic (CKM) systems are interconnected through complex and multifactorial interaction and neurohormonal feedback mechanisms. In this webinar, Dr. Janaka Karalliedde from the Guy’s and St Thomas’ Hospital, King’s College London, the United Kingdom, highlights the significance of recognizing and addressing all three conditions, type 2 diabetes mellitus (T2D), diabetic kidney disease (DKD) and heart failure (HF), as well as the impact of empagliflozin on renal outcomes, cardiovascular benefits and mortality risks.

Dr. Karalliedde further emphasized the need for early intervention and the role of primary care physicians in screening and treating patients early with sodium-glucose cotransporter 2 inhibitors (SGLT2is) such as empagliflozin to maximize the potential benefits of the drug on the CKM systems and patients’ quality of life.

 

Get access to our exclusive articles.
Related Articles